GSK's Avodart reduces prostate cancer progression in REDEEM
This article was originally published in Scrip
GlaxoSmithKline's BPH treatment Avodart (dutasteride) could be a beneficial adjunctive treatment for men with low-risk prostate cancer who choose active surveillance over standard treatments, a new study suggests.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.